Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.

[1]  R. Dahl,et al.  Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance , 2016, Journal of aerosol medicine and pulmonary drug delivery.

[2]  D. Halpin,et al.  The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial. , 2016, The journal of allergy and clinical immunology. In practice.

[3]  E. Bleecker,et al.  Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. , 2015, The Lancet. Respiratory medicine.

[4]  K. Ohta,et al.  Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study , 2015, PloS one.

[5]  E. Pizzichini,et al.  Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. , 2015, Respiratory medicine.

[6]  S. Korn,et al.  Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma , 2014, Respiratory Research.

[7]  C. Furberg,et al.  Tiotropium and the risk of death in COPD. , 2014, The New England journal of medicine.

[8]  D. V. Hoff,et al.  Tiotropium and the Risk of Death in COPD , 2014 .

[9]  Michael Engel,et al.  Tiotropium in asthma poorly controlled with standard combination therapy. , 2012, The New England journal of medicine.

[10]  E. Bateman,et al.  Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. , 2011, The Journal of allergy and clinical immunology.

[11]  H. Kerstjens,et al.  Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. , 2011, The Journal of allergy and clinical immunology.

[12]  D. Olivieri,et al.  Understanding patients with asthma and COPD: insights from a European study. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[13]  A. Fryer,et al.  Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD , 2011, British journal of pharmacology.

[14]  P. Demoly,et al.  Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK , 2009, European Respiratory Review.

[15]  N. Barnes,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. , 2004, American journal of respiratory and critical care medicine.

[16]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .